Melatonin Pharmacological Blood Levels Increase Total Antioxidant Capacity in Critically Ill Patients

In this study, the aim was to test the biochemical effects of melatonin supplementation in Intensive Care Unit (ICU) patients, since their blood levels are decreased. Sixty-four patients were enrolled in the study. From the evening of the 3rd ICU day, patients were randomized to receive oral melatonin (3 mg, group M) or placebo (group P) twice daily, at 20:00 and 24:00, until discharged. Blood was taken (at 00:00 and 14:00), on the 3rd ICU day to assess basal nocturnal melatonin values, and then during the treatment period on the 4th and 8th ICU days. Melatonin, total antioxidant capacity, and oxidative stress were evaluated in serum. Melatonin circadian rhythm before treatment was similar in the two groups, with a partial preservation of the cycle. Four hours from the 1st administration (4th ICU day, 00:00), melatonin levels increased to 2514 (982.3; 7148) pg·mL−1 in group M vs. 20.3 (14.7; 62.3) pg·mL−1 in group P (p < 0.001). After five treatment days (8th ICU day), melatonin absorption showed a repetitive trend in group M, while in group P nocturnal secretion (00:00) was impaired: 20 (11.5; 34.5) pg·mL−1 vs. 33.8 (25.0; 62.2) on the 3rd day (p = 0.029). Immediately from the beginning of treatment, the total antioxidant capacity was significantly higher in melatonin treated subjects at 00:00; a significant correlation was found between total antioxidant capacity and blood melatonin values (ρ = 0.328; p < 0.001). The proposed enteral administration protocol was adequate, even in the early phase, to enhance melatonin blood levels and to protect the patients from oxidative stress. The antioxidant effect of melatonin could play a meaningful role in the care and well-being of these patients.

[1]  R. Reiter,et al.  Melatonin as an antioxidant: under promises but over delivers , 2016, Journal of pineal research.

[2]  J. Bellapart,et al.  Pharmacokinetics of a novel dosing regimen of oral melatonin in critically ill patients , 2016, Clinical chemistry and laboratory medicine.

[3]  A. Morabito,et al.  Melatonin reduces the need for sedation in ICU patients: a randomized controlled trial. , 2015, Minerva anestesiologica.

[4]  R. Reiter,et al.  Melatonin: an ancient molecule that makes oxygen metabolically tolerable , 2015, Journal of pineal research.

[5]  Antonio Martinez-Nicolas,et al.  Disruption of Circadian Rhythms and Delirium, Sleep Impairment and Sepsis in Critically ill Patients. Potential Therapeutic Implications for Increased Light-Dark Contrast and Melatonin Therapy in an ICU Environment. , 2015, Current pharmaceutical design.

[6]  Yiqiang Zhang,et al.  Melatonin: a well‐documented antioxidant with conditional pro‐oxidant actions , 2014, Journal of pineal research.

[7]  G. Favero,et al.  Antitumour activity of melatonin in a mouse model of human prostate cancer: relationship with hypoxia signalling , 2014, Journal of pineal research.

[8]  I. Sadowska-Bartosz,et al.  Melatonin Acts as Antioxidant and Improves Sleep in MS Patients , 2014, Neurochemical Research.

[9]  H. M. Schaefer,et al.  The proper time for antioxidant consumption , 2014, Physiology & Behavior.

[10]  G. Cameron,et al.  Melatonin as a potential therapy for sepsis: a phase I dose escalation study and an ex vivo whole blood model under conditions of sepsis , 2014, Journal of pineal research.

[11]  D. Acuña-Castroviejo,et al.  The beneficial effects of melatonin against heart mitochondrial impairment during sepsis: inhibition of iNOS and preservation of nNOS , 2014, Journal of pineal research.

[12]  Daniel Kiefer,et al.  Melatonin Receptors Mediate Improvements of Survival in a Model of Polymicrobial Sepsis , 2014, Critical care medicine.

[13]  L. Rodella,et al.  Endothelial and vascular smooth muscle cell dysfunction mediated by cyclophylin A and the atheroprotective effects of melatonin. , 2013, Life sciences.

[14]  L. Rodella,et al.  Aging and vascular dysfunction: beneficial melatonin effects , 2011, AGE.

[15]  J. Bellapart,et al.  Potential use of melatonin in sleep and delirium in the critically ill. , 2012, British journal of anaesthesia.

[16]  B. Cotton,et al.  Antioxidants and micronutrient supplementation in trauma patients , 2012, Current opinion in clinical nutrition and metabolic care.

[17]  P. Bartmann,et al.  Melatonin status in pediatric intensive care patients with sepsis* , 2012, Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies.

[18]  M. Andrades,et al.  Bench-to-bedside review: Sepsis - from the redox point of view , 2011, Critical care.

[19]  H. Mühl,et al.  Inducible NO synthase and antibacterial host defence in times of Th17/Th22/T22 immunity , 2011, Cellular microbiology.

[20]  A. Alajbegović,et al.  Serum total antioxidant capacity in patients with multiple sclerosis. , 2011, Bosnian journal of basic medical sciences.

[21]  P. Magni,et al.  Pharmacokinetics of orally administered melatonin in critically ill patients , 2010, Journal of pineal research.

[22]  L. Rodella,et al.  Melatonin delivery in solid lipid nanoparticles: prevention of cyclosporine A induced cardiac damage , 2009, Journal of pineal research.

[23]  C. Minelli,et al.  Melatonin therapy to improve nocturnal sleep in critically ill patients: encouraging results from a small randomised controlled trial , 2008, Critical care.

[24]  Greg Atkinson,et al.  Jet lag: trends and coping strategies , 2007, The Lancet.

[25]  C. Dodt,et al.  Nocturnal melatonin concentration is correlated with illness severity in patients with septic disease , 2006, Intensive Care Medicine.

[26]  G. Mills,et al.  Melatonin: possible implications for the postoperative and critically ill patient , 2006, Intensive Care Medicine.

[27]  Josep M. Guerrero,et al.  Beneficial pleiotropic actions of melatonin in an experimental model of septic shock in mice: regulation of pro‐/anti‐inflammatory cytokine network, protection against oxidative damage and anti‐apoptotic effects , 2005, Journal of pineal research.

[28]  G. Van den Berghe,et al.  Endocrine modifications and interventions during critical illness , 2004, The Proceedings of the Nutrition Society.

[29]  U. Frisk,et al.  Low melatonin excretion during mechanical ventilation in the intensive care unit. , 2004, Clinical science.

[30]  C. Alling,et al.  Abolished circadian rhythm of melatonin secretion in sedated and artificially ventilated intensive care patients , 2004, Acta anaesthesiologica Scandinavica.

[31]  G. Mills,et al.  Sleep disruption in critically ill patients – pharmacological considerations , 2004, Anaesthesia.

[32]  H. Kuwano,et al.  Correlation between serum melatonin circadian rhythm and intensive care unit psychosis after thoracic esophagectomy. , 2003, Surgery.

[33]  W. Marktl,et al.  Impaired circadian rhythm of melatonin secretion in sedated critically ill patients with severe sepsis. , 2002, Critical care medicine.

[34]  S. Cuzzocrea,et al.  Effects of Melatonin Treatment in Septic Newborns , 2001, Pediatric Research.

[35]  J S Bertino,et al.  The Absolute Bioavailability of Oral Melatonin , 2000, Journal of clinical pharmacology.

[36]  C. Vaquerizo Alonso,et al.  Guidelines for specialized nutritional and metabolic support in the critically-ill patient: update. Consensus SEMICYUC-SENPE: septic patient. , 2011, Nutricion hospitalaria.

[37]  M. Degli Esposti.  Mitochondria in apoptosis: past, present and future. , 2004, Biochemical Society transactions.

[38]  D. Kunz,et al.  Melatonin in patients with reduced REM sleep duration: two randomized controlled trials. , 2004, The Journal of clinical endocrinology and metabolism.